Phase 1 Study of Safety, Tolerability, PK, and PD of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with T2DM

被引：1
|
作者：
Ohwaki, Kenji
Furihata, Kenichi
Nasu, Risa
Oura, Tomonori
Imori, Makoto
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-742-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
742-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Tolerability, Safety, PK/PD of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients in China and US
    Liu, Ying
    Lv, Yuan
    Guo, Xiaohui
    Zhao, Caiyun
    Zhang, Junqing
    Wei, Minji
    Tracey, Gregory J.
    Lasseter, Kenneth C.
    Xu, Michael
    DIABETES, 2017, 66 : A296 - A296
  • [2] Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
    Kazda, Christof M.
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Wullenweber, Paula
    Haupt, Axel
    Frias, Juan P.
    DIABETES, 2021, 70
  • [3] Tolerability, Safety, Pharmacokinetics, and Therapeutic Efficacy of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients
    Liu, Edy
    Guo, Xiaohui
    Tracey, Gregory
    Willett, Michael
    Lasseter, Kenneth
    Huang, Gavin
    Lv, Wei
    Zhou, Joe
    Zhang, Lihong
    Xu, Michael M.
    DIABETES, 2016, 65 : A268 - A268
  • [4] Safety, Pharmacokinetics, and Pharmacodynamics of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial
    Nasu, Risa
    Oura, Tomonori
    Ohwaki, Kenji
    Imori, Makoto
    Furihata, Kenichi
    DIABETES, 2022, 71
  • [5] ONCE-WEEKLY BASAL INSULIN FC (BIF) DEMONSTRATED SIMILAR GLYCEMIC CONTROL TO ONCE-DAILY INSULIN DEGLUDEC (DEG) IN INSULIN-NAIVE PATIENTS WITH TYPE 2 DIABETES (T2D)
    Bue-Valleskey, J.
    Kazda, C.
    Ma, C.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Swan, J.
    Haupt, A.
    Frias, J. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A193 - A193
  • [6] Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
    Frias, Juan
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Syring, Kristen
    Wullenweber, Paula
    Haupt, Axel
    Kazda, Christof
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (03): : 158 - 168
  • [7] Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
    Kazda, Christof M.
    Bue-Valleskey, Juliana M.
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Wullenweber, Paula
    Haupt, Axel
    Dahl, Dominik
    DIABETES CARE, 2023, 46 (05) : 1052 - 1059
  • [8] Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Once-Weekly Dulaglutide in Elderly Patients with Type 2 Diabetes (T2D)
    Loghin, Corina
    Schneck, Karen B.
    Cui, Xuewei
    Chien, Jenny Y.
    DIABETES, 2015, 64 : A259 - A259
  • [9] A NOVEL ONCE-WEEKLY BASAL INSULIN FC ACHIEVED SIMILAR GLYCEMIC CONTROL WITH A COMPARABLE SAFETY PROFILE VERSUS INSULIN DEGLUDEC IN PATIENTS WITH TYPE 1 DIABETES
    Kazda, C.
    Bue-Valleskey, J.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Wullenweber, P.
    Haupt, A.
    Dahl, D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A71 - A72
  • [10] DURATION-1 Extension: Efficacy and Tolerability of Exenatide Once Weekly (QW) Over 6 Years in Patients with T2DM
    Henry, Robert R.
    Klein, Eric J.
    Malloy, Jaret
    Griffin, Peter S.
    Zhou, Ming
    Iqbal, Nayyar
    DIABETES, 2014, 63 : A247 - A247
12345